Table 2.
Effect of OMEE on CDDP-induced oxidative/nitrosative damage.
| Markers | Control | CDDP | |||
|---|---|---|---|---|---|
| Vehicle | OMEE | ||||
| MDA | (nmol/g.protein) | 5.937 ± 0.595 | 12.029 ± 0.711 a | 5.628 ± 0.527 b | (−107.74%) |
| NO | (Mmol/g.protein) | 171.602 ± 9.944 | 312.555 ± 19.110 a | 187.258 ± 24.846 b | (−73.02%) |
| GSH | (mg/g.protein) | 22.719 ± 2.885 | 13.621 ± 2.098 a | 22.378 ± 1.591 b | (38.56%) |
| SOD | (U/g.protein) | 993.255 ± 74.932 | 655.220 ± 87.654 a | 991.462 ± 105.168 b | (35.42%) |
| CAT | (U/g.protein) | 11.054 ± 0.502 | 5.730 ± 0.776 a | 11.081 ± 1.161 b | (48.42%) |
All data are mean ± SEM of 6 rats; a: significant at p < 0.05 as compared to control group; b: significant at p < 0.05 as compared to CDDP group; (%) is the % improvement of each treatment against CDDP. OMEE: Originum majorana ethanolic extract; CDDP: Cis-Diaminedichloroplatinum (II); MDA: Malondialdehyde; NO: Nitric oxide; GSH: Glutathione reduced; SOD: Superoxide dismutase; CAT: Catalase.